

esmo.org

ESMO Virtual Advanced Course on Biomarkers for Precision Medicine

Programme

ESMO VIRTUAL Advanced Course

13-14 SEPTEMBER 2021

Co-Chairs Albrecht Stenzinger, Germany Daniel S.W. Tan, Singapore

ESMO VIRTUAL ADVANCED COURSE PROGRAMME ON BIOMARKERS FOR PRECISION MEDICINE

13-14 September 2021

CO-CHAIRS: Albrecht Stenzinger, Germany Daniel S. W. Tan, Singapore SPEAKERS: Catherine Alix-Panabières, France Francesca Finotello, Austria John B.A.G. Haanen, Netherlands Anand D. Jeyasekharan, Singapore Tony K. H. Lim, Singapore Sherene Loi, Australia Catia Moutinho, Australia Jorge Reis-Filho, United States Iain B. H. Tan, Singapore Tira J. Y. Tan, Singapore Joe P. S. Yeong, Singapore

LEARNING OBJECTIVES

- An increasing number of therapeutics that require biomarkers testing are available for clinical use or are in advanced phase of clinical development
- Different technologies can be used for biomarker testing depending on the nature of the biomarker and the availability of biological samples
- The increasing use of large panels for comprehensive genomic profiling raises issues on data interpretation that require a multidisciplinary approach
- Monitoring the molecular evolution of the disease might allow the identification of resistance mechanisms and the development of more effective therapeutic strategies
- The identification of germline variants requires the activation of genetic counselling programs for patients and their families

ACCREDITATION

The programme of this event has been accredited with 7 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office Education Department Via Ginevra 4 6900 Lugano Switzerland Email: courses@esmo.org www.esmo.org



Monday, 13 September 2021

Welcome and introduction
Welcome and Learning Objectives Introduction Albrecht Stenzinger, DE and Daniel S. W. Tan, SG
Session 1 – Genomic alterations
Overview and assays commonly used, Tony K. H. Lim, SG Practical interpretation, Learning points for bioinformatics, Francesca Finotello, AT Discussion
Break
Session 2 – Gene fusion
Technical aspects, Albrecht Stenzinger, DE Clinics (NTRK, RET, ROS1, FGFR2, NRG1, etc,), Daniel S. W. Tan, SG Discussion
Session 3 – Homologous Repair Deficiency
Technical aspects and definition, Anand D. Jeyasekharan, SG Clinics (ovarian, mPCA, PDAC,), Tira J. Y. Tan, SG Discussion
Session 4 – Emerging technologies
Leveraging AI to maximize value of digital pathology, Jorge Reis Filho, US Understanding the emerging role of single cells genomics, Catia Moutinho, AU Discussion

Tuesday, 14 September 2021

Session 5 – Liquid biopsy

20'	Technical aspects for CTCs and nucleic acid, Catherine Alix-Panabières, FR
20'	Clinics (trials most importantly), Iain B. H. Tan, SG
20'	Discussion

15:00-16:00

16:00-17:15 Session 6 – Immuno-oncology biomarkers (IO)

- 20' Current biomarkers in clinical use, Sherene Loi, AU
- 20' Tissue multiplexed biomarkers, Joe P. S. Yeong, SG
- 20' Neo antigens as targets for cancer vaccines and adoptive T-cell therapy, John B.A.G. Haanen, NL
- 15' Discussion
- 17:15-17:25 Break
- 17:25-18:45 Workshop sessions

Workshop 1 Interactive Molecular Tumour Board Albrecht Stenzinger, DE and Daniel S. W. Tan, SG, 15' Introduction based on clinical cases presented by speakers 25' Discussion

- Workshop 2 Interactive Practical Session
 - Tony K. H. Lim, SG and Tira J. Y. Tan, SG
 - 40' Clinical cases in assay challenges interpretation with discussion after each question
- 18:45-18:50 Synthesis and wrap-up